Medical Imaging in Drug Development

Lecture / Panel
Open to the Public

Medical Imaging in Drug Development


Shuyan Dan

Executive Director, 

Imaging, Translational Sciences and Diagnostics, Bristol-Myers Squibb



Scientists and experts at Bristol Myers Squibb are working to revolutionize the drug development process with sophisticated scientific strategies driven by technology. The company is accelerating and evolving its pipeline to get therapies to patients faster by using computer science, advanced clinical trial solutions, and robust digital platforms. Much of this work centers around medical imaging technologies that include ultrasounds, X-rays, and computed tomography (CT) scans. With molecular, translational, imaging, clinical, wearable, and real-world data, they create a picture that advances the understanding of the biology of various diseases. Data coupled with predictive machine learning methods helps to ask and answer questions concerning a medical condition, the drug, and the types of patients that can be helped.

After receiving a BS and MS in Biomedical Engineering from Tsinghua University in Beijing, China, Dr. Du came to the US to pursue a PhD degree in Biomedical Engineering at Columbia University in the City of New York. After completing this degree, she joined Bristol-Myers Squibb in 2008. There, she held various positions in the imaging division in Princeton, NJ, before being promoted to Executive Director of Imaging, Translational Sciences, and Diagnostics.



Medical Imaging in Drug Development
Colored 3D axial computed tomography (CT) scan of human lungs seen from above with a tumor (blue, far left) in the upper lobe of the left lung. Also seen here is collapse of the surrounding lung area, and pleural adhesions.